檢索結果 - Marvella E. Ford
- Showing 1 - 16 results of 16
-
1
-
2
-
3
-
4
-
5
-
6
-
7
The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. 由 Aimee E. Belanger, Gurdyal S. Besra, Marvella E. Ford, Katarı́na Mikušová, John T. Belisle, Patrick J. Brennan, Julia M. Inamine
出版 1996Artigo -
8
-
9
-
10
Recruitment of racial and ethnic minorities to clinical trials conducted within specialty clinics: an intervention mapping approach 由 Rossybelle P. Amorrortu, Mariana Arévalo, Sally W. Vernon, Arch G. Mainous, Vanessa Diaz, M. Diane McKee, Marvella E. Ford, Barbara C. Tilley
出版 2018Artigo -
11
Unequal Burden of Disease, Unequal Participation in Clinical Trials: Solutions from African American and Latino Community Members 由 Marvella E. Ford, Laura A. Siminoff, E. Elisabeth Pickelsimer, Arch G. Mainous, Daniel W. Smith, Vanessa Diaz, Lisa Söderström, Melanie Jefferson, Barbara C. Tilley
出版 2013Artigo -
12
-
13
-
14
Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society Statement 由 M. Patricia Rivera, Hormuzd A. Katki, Nichole T. Tanner, Matthew Triplette, Lori C. Sakoda, Renda Soylemez Wiener, Roberto Cardarelli, Lisa Carter‐Harris, Kristina Crothers, Joelle T. Fathi, Marvella E. Ford, Robert A. Smith, Robert A. Winn, Juan P. Wisnivesky, Louise M. Henderson, Melinda C. Aldrich
出版 2020Artigo -
15
US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials 由 Jeanne M. Regnante, Nicole Richie, Lola A. Fashoyin‐Aje, Michelle Vichnin, Marvella E. Ford, Upal Roy, K. C. Turner, Laura Lee Hall, Evelyn González, Nestor F. Esnaola, Luther T. Clark, Homer Adams, Olatunji B. Alese, Keerthi Gogineni, Lorna H. McNeill, Daniel G. Petereit, Ify Sargeant, Julie Dang, Coleman K. Obasaju, Quita Highsmith, Simon J. Craddock Lee, Spencer C. Hoover, Erin L. Williams, Moon S. Chen
出版 2019Artigo -
16
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention 由 K. Walter, Marvella E. Ford, Mathew J. Gregoski, Rita Kramer, Kendrea D. Knight, Laura Spruill, Lourdes M. Nogueira, Bradley A. Krisanits, Van Phan, Amanda C. La Rue, Michael B. Lilly, Stefan Ambs, King Chan, Tonya F. Turner, Heidi Varner, Shweta Singh, Jaime Uribarri, Elizabeth Garrett‐Mayer, Kent Armeson, Ebony J. Hilton, Mark J. Clair, Marian H. Taylor, Andrea M. Abbott, Victoria J. Findlay, Lindsay L. Peterson, Gayenell Magwood, David P. Turner
出版 2018Artigo
相關主題
Medicine
Internal medicine
Cancer
Sociology
Pathology
Family medicine
Gerontology
Nursing
Environmental health
Ethnic group
Population
Psychology
Anthropology
Biology
Clinical trial
Public health
Economic growth
Economics
Health care
Health equity
Law
Political science
Intervention (counseling)
Oncology
Accounting
Accrual
Biochemistry
Breast cancer
Business
Cancer registry